2024 Partners
genOway
Expertise Partner
For the past 20 years, genOway has aimed to improve the predictability and reliability of preclinical data by designing models of high physiological relevancy to best meet researchers’ needs. With a catalog of humanized immune checkpoint mouse models, and mice featuring the human immune system, genOway possesses a broad set of tools to help decipher the mechanism of action as well as the efficacy and safety of drugs targeting the immune system. Additionally, genOway owns strong intellectual property rights, combining patents and licensing agreements, enabling the company to provide end users the necessary freedom to operate.
Applied BioMath
Expertise Partner
Applied BioMath applies biosimulation services and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Applied BioMath recently joined Certara in a strategic acquisition to form the life sciences industry's largest team of experts in quantitative systems pharmacology (QSP). Certara’s clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Nextera
Expertise Partner
Nextera opens a path towards disease-specific understanding and therapy in cancer and autoimmunity by intersecting the problem at the core - the adaptive immune receptor synapse - translating to targeted disease-specific treatment without compromising the patient’s health. NextCore developed TCR-Like antibodies have exquisite specificity and unique potency towards disease-specific pHLA targets addressing the unmet demand for safe and improved targeted immunotherapy.
Alloy Therapeutics
Expertise Partner
Alloy’s Keyway TCR Discovery is a proprietary, integrated, end-to-end service for generating highly-specific
therapeutically-optimized TCR mimic leads. From immunizing our industry-leading ATX-Gx mice with high-quality protein-HLA complexes, to pairing in vitro and AI/ML capabilities for broad developability and specificity screening, to state-of-art engineering and bespoke functional screening capabilities. Integrating our discovery capabilities with our expertise in multi specifics engineering, Alloy is well placed to meet the needs of the rapidly developing therapeutic T-Cell Engager field
